Obesity is associated with myelin oligodendrocyte glycoprotein antibody-associated disease in acute optic neuritis
© 2022. The Author(s)..
Optic neuritis (ON) is a frequent presentation at onset of multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). The pathophysiology underlying these diseases, especially MOGAD, is still being elucidated. While obesity has been reported to potentially be a risk factor for MS, this has not been explored in NMOSD or MOGAD. We aimed to investigate a possible association between obesity (body mass index [BMI] > 30 kg/m2) in patients with MOGAD, aquaporin 4-IgG positive NMOSD (AQP4-IgG+ NMOSD) or MS. In this multicenter non-interventional retrospective study, data was collected from patients with a first ever demyelinating attack of ON subsequently diagnosed with MOGAD (n = 44), AQP4-IgG+ NMOSD (n = 49) or MS (n = 90) between 2005 and 2020. The following data was collected: age, sex, ethnicity, BMI (documented before corticosteroid treatment), and the ON etiology after diagnostic work-up. A mixed model analysis was performed to assess the potential of obesity or BMI to predict MOGAD-ON, and to distinguish MOGAD-ON from AQP4-IgG+ NMOSD-ON and MS-ON. Main outcome measures included BMI in patients with acute ON and subsequent diagnosis of MOGAD, AQP4-IgG+ NMOSD or MS. A higher BMI was significantly associated with a diagnosis of MOGAD-ON (p < 0.001); in MOGAD patients the mean BMI was 31.6 kg/m2 (standard deviation (SD) 7.2), while the mean BMI was 24.7 kg/m2 (SD 5.3) in AQP4-IgG+ NMOSD patients, and 26.9 kg/m2 (SD 6.2) in MS patients. Mixed-effects multinomial logistic regression, adjusted for age and sex, with obesity as a binary variable, revealed that obesity was associated with a higher odds ratio (OR) of a subsequent MOGAD diagnosis (OR 5.466, 95% CI [2.039, 14.650], p = 0.001) in contradistinction with AQP4-IgG+ NMOSD. This study suggests an association between obesity and MOGAD. Our findings require further exploration, but could have significant pathophysiologic implications if confirmed in larger prospective studies.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Scientific reports - 12(2022), 1 vom: 09. Dez., Seite 21312 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Stiebel-Kalish, Hadas [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Aquaporin 4 |
|---|
| Anmerkungen: |
Date Completed 16.12.2022 Date Revised 24.02.2023 published: Electronic ErratumIn: Sci Rep. 2023 Feb 20;13(1):2944. - PMID 36807557 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41598-022-21592-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350066388 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350066388 | ||
| 003 | DE-627 | ||
| 005 | 20231226205658.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41598-022-21592-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1166.xml |
| 035 | |a (DE-627)NLM350066388 | ||
| 035 | |a (NLM)36494385 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Stiebel-Kalish, Hadas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Obesity is associated with myelin oligodendrocyte glycoprotein antibody-associated disease in acute optic neuritis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2022 | ||
| 500 | |a Date Revised 24.02.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ErratumIn: Sci Rep. 2023 Feb 20;13(1):2944. - PMID 36807557 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a Optic neuritis (ON) is a frequent presentation at onset of multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). The pathophysiology underlying these diseases, especially MOGAD, is still being elucidated. While obesity has been reported to potentially be a risk factor for MS, this has not been explored in NMOSD or MOGAD. We aimed to investigate a possible association between obesity (body mass index [BMI] > 30 kg/m2) in patients with MOGAD, aquaporin 4-IgG positive NMOSD (AQP4-IgG+ NMOSD) or MS. In this multicenter non-interventional retrospective study, data was collected from patients with a first ever demyelinating attack of ON subsequently diagnosed with MOGAD (n = 44), AQP4-IgG+ NMOSD (n = 49) or MS (n = 90) between 2005 and 2020. The following data was collected: age, sex, ethnicity, BMI (documented before corticosteroid treatment), and the ON etiology after diagnostic work-up. A mixed model analysis was performed to assess the potential of obesity or BMI to predict MOGAD-ON, and to distinguish MOGAD-ON from AQP4-IgG+ NMOSD-ON and MS-ON. Main outcome measures included BMI in patients with acute ON and subsequent diagnosis of MOGAD, AQP4-IgG+ NMOSD or MS. A higher BMI was significantly associated with a diagnosis of MOGAD-ON (p < 0.001); in MOGAD patients the mean BMI was 31.6 kg/m2 (standard deviation (SD) 7.2), while the mean BMI was 24.7 kg/m2 (SD 5.3) in AQP4-IgG+ NMOSD patients, and 26.9 kg/m2 (SD 6.2) in MS patients. Mixed-effects multinomial logistic regression, adjusted for age and sex, with obesity as a binary variable, revealed that obesity was associated with a higher odds ratio (OR) of a subsequent MOGAD diagnosis (OR 5.466, 95% CI [2.039, 14.650], p = 0.001) in contradistinction with AQP4-IgG+ NMOSD. This study suggests an association between obesity and MOGAD. Our findings require further exploration, but could have significant pathophysiologic implications if confirmed in larger prospective studies | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Myelin-Oligodendrocyte Glycoprotein |2 NLM | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Aquaporin 4 |2 NLM | |
| 700 | 1 | |a Rubarth, Kerstin |e verfasserin |4 aut | |
| 700 | 1 | |a Shouchane-Blum, Karny |e verfasserin |4 aut | |
| 700 | 1 | |a Tiosano, Alon |e verfasserin |4 aut | |
| 700 | 1 | |a Lotan, Itay |e verfasserin |4 aut | |
| 700 | 1 | |a Hellmann, Mark A |e verfasserin |4 aut | |
| 700 | 1 | |a Wilf-Yarkoni, Adi |e verfasserin |4 aut | |
| 700 | 1 | |a Bialer, Omer |e verfasserin |4 aut | |
| 700 | 1 | |a Flanagan, Eoin P |e verfasserin |4 aut | |
| 700 | 1 | |a Pittock, Sean J |e verfasserin |4 aut | |
| 700 | 1 | |a Bhatti, M Tariq |e verfasserin |4 aut | |
| 700 | 1 | |a Schmitz-Hübsch, Tanja |e verfasserin |4 aut | |
| 700 | 1 | |a Paul, Friedemann |e verfasserin |4 aut | |
| 700 | 1 | |a Asseyer, Susanna |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, John J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Scientific reports |d 2011 |g 12(2022), 1 vom: 09. Dez., Seite 21312 |w (DE-627)NLM215703936 |x 2045-2322 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g number:1 |g day:09 |g month:12 |g pages:21312 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41598-022-21592-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |e 1 |b 09 |c 12 |h 21312 | ||